WO2002059102A3 - Derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation - Google Patents

Derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation Download PDF

Info

Publication number
WO2002059102A3
WO2002059102A3 PCT/FR2002/000279 FR0200279W WO02059102A3 WO 2002059102 A3 WO2002059102 A3 WO 2002059102A3 FR 0200279 W FR0200279 W FR 0200279W WO 02059102 A3 WO02059102 A3 WO 02059102A3
Authority
WO
WIPO (PCT)
Prior art keywords
medicines
aryl
optionally substituted
pharmaceutical compositions
urea derivatives
Prior art date
Application number
PCT/FR2002/000279
Other languages
English (en)
Other versions
WO2002059102A2 (fr
Inventor
Pierre Deprez
Marcel Patek
Original Assignee
Aventis Pharma Sa
Pierre Deprez
Marcel Patek
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa, Pierre Deprez, Marcel Patek filed Critical Aventis Pharma Sa
Priority to JP2002559404A priority Critical patent/JP4084189B2/ja
Priority to CA002435647A priority patent/CA2435647A1/fr
Priority to AU2002233463A priority patent/AU2002233463A1/en
Priority to MXPA03006538A priority patent/MXPA03006538A/es
Priority to US10/466,571 priority patent/US20040053925A1/en
Priority to EP02700386A priority patent/EP1358171A2/fr
Publication of WO2002059102A2 publication Critical patent/WO2002059102A2/fr
Publication of WO2002059102A3 publication Critical patent/WO2002059102A3/fr
Priority to US11/644,343 priority patent/US7605261B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
    • C07C275/20—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton
    • C07C275/24—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/32—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms
    • C07C275/34—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

L'invention concerne les nouveaux produits de formule (I): dans laquelle: Y représente oxygène ou soufre, Z représente C=CH2, CH-CH3 ou CH2, R1 représente hydrogène, morpholinyle ou le radical (II). Dans lequel les deux atomes d'azote sont linéaires ou forment un radical cyclique, X représente carbonyle, alkylène ou alkènylène linéaire ou ramifié renferment au plus 6 atomes de carbone éventuellement interrompu oxygène ou soufre, R4, R5 et R6 représentent hydrogène, un groupement protecteur de l'azote, alkyle, cycloalkyle, aryle et arylalkyle éventuellement substitués, R2 représente alkyle éventuellement substitué par aryle, hétéoaryle ou NR4R5, R3 représente alkyle, cycloalkyle, aryle, hétéroaryle, arylalkyle ou hétéroarylalkyle éventuellement substitués, ces produits étant sous toutes les formes isomères et les sels, à titre de médicaments.
PCT/FR2002/000279 2001-01-26 2002-01-23 Derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation WO2002059102A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
JP2002559404A JP4084189B2 (ja) 2001-01-26 2002-01-23 尿素の新誘導体、それらの製造方法、それらの薬剤としての使用、製薬組成物及び新規な用途
CA002435647A CA2435647A1 (fr) 2001-01-26 2002-01-23 Derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation
AU2002233463A AU2002233463A1 (en) 2001-01-26 2002-01-23 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and use
MXPA03006538A MXPA03006538A (es) 2001-01-26 2002-01-23 Nuevos derivados de urea, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion.
US10/466,571 US20040053925A1 (en) 2001-01-26 2002-01-23 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use
EP02700386A EP1358171A2 (fr) 2001-01-26 2002-01-23 Derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation
US11/644,343 US7605261B2 (en) 2001-01-26 2006-12-22 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0101054 2001-01-26
FR0101054A FR2820136A1 (fr) 2001-01-26 2001-01-26 Nouveaux derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10466571 A-371-Of-International 2002-01-23
US11/644,343 Continuation US7605261B2 (en) 2001-01-26 2006-12-22 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use

Publications (2)

Publication Number Publication Date
WO2002059102A2 WO2002059102A2 (fr) 2002-08-01
WO2002059102A3 true WO2002059102A3 (fr) 2003-01-09

Family

ID=8859262

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/000279 WO2002059102A2 (fr) 2001-01-26 2002-01-23 Derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation

Country Status (8)

Country Link
US (2) US20040053925A1 (fr)
EP (1) EP1358171A2 (fr)
JP (1) JP4084189B2 (fr)
AU (1) AU2002233463A1 (fr)
CA (1) CA2435647A1 (fr)
FR (1) FR2820136A1 (fr)
MX (1) MXPA03006538A (fr)
WO (1) WO2002059102A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2298311B1 (fr) 1999-01-13 2012-05-09 Bayer HealthCare LLC Urées de diphényle à substitution omega-carboxyaryle en tant qu'inhibiteurs de la p38 kinase
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
MXPA04007832A (es) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aril-ureas con actividad inhibitoria de angiogenesis.
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
ATE366108T1 (de) 2003-05-20 2007-07-15 Bayer Pharmaceuticals Corp Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
UA84156C2 (ru) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Фторозамещённая омега-карбоксиарилдифенилмочевина для лечения и профилактики болезней и состояний
US20060086280A1 (en) * 2004-06-15 2006-04-27 Henri Duong Anesthetic bullets using for guns and anesthetic weapons
FR2885129B1 (fr) * 2005-04-29 2007-06-15 Proskelia Sas Nouveaux derives de l'ureee substituee parun thiazole ou benzothiazole, leur procede de preparation, leur application a titre de medicaments, les compositions pharmaceutiques les renfermant et utilisation.
EP1965805B1 (fr) * 2005-11-25 2009-12-02 Galapagos SAS Dérivés de l'urée utiles comme modulateurs des récepteurs du calcium
CN101437490A (zh) 2006-04-20 2009-05-20 安美基公司 稳定乳液配方
GB0613674D0 (en) * 2006-07-10 2006-08-16 Proskelia Sas Derivatives of urea and related diamines, methods for their manufacture, and uses therefor
EP2139462B1 (fr) 2007-03-30 2014-01-22 Amgen Inc. Composés calcimimétiques pour leur utilisation dans le traitement des troubles intestinaux
WO2009009122A2 (fr) * 2007-07-10 2009-01-15 Amgen Inc. Dérivés de l'urée et de diamines associées, leurs procédés de fabrication, et leurs utilisations
CA2716780A1 (fr) 2008-02-25 2009-09-03 National University Corporation Hokkaido University Agent prophylactique ou therapeutique pour le diabete ou l'obesite
JPWO2009119554A1 (ja) 2008-03-24 2011-07-21 味の素株式会社 消化管の重炭酸分泌促進剤
JP5533648B2 (ja) 2008-04-17 2014-06-25 味の素株式会社 免疫賦活剤
WO2010103429A1 (fr) 2009-03-10 2010-09-16 Pfizer Inc. Dérivés de l'acide 1,1-(diméthyl-éthylamino)-2-hydroxy-propoxy]-éthyl}-3-méthyl-biphényl-4-carboxylique utiles en tant qu'antagonistes des récepteurs du calcium
WO2010104882A1 (fr) 2009-03-10 2010-09-16 Amgen Inc. Procédés de modulation de la motilité des spermatozoïdes
EP2435400A2 (fr) 2009-05-27 2012-04-04 Leo Pharma A/S Composés inédits modulant les récepteurs du calcium et leur utilisation pharmaceutique
WO2010136037A1 (fr) 2009-05-27 2010-12-02 Leo Pharma A/S Nouveaux composés modulant le récepteur sensible au calcium, et leur utilisation pharmaceutique
AU2011289407B2 (en) 2010-08-11 2015-06-18 Philadelphia Health & Education Corporation Novel D3 dopamine receptor agonists to treat dyskinesia in Parkinson's disease
JP2014508103A (ja) 2010-11-26 2014-04-03 レオ ファーマ アクティーゼルスカブ カルシウム感知受容体活性化合物
CN103228619A (zh) 2010-11-26 2013-07-31 利奥制药有限公司 钙传感受体活性化合物
RU2013128973A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Соединения, активные в отношении кальций-чувствительных рецепторов
RU2013128950A (ru) 2010-11-26 2015-01-10 Лео Фарма А/С Замещенные циклопентилазины в качестве casr-активных соединений

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2001791A1 (fr) * 1968-02-13 1969-10-03 Ciba Geigy
EP0153576A2 (fr) * 1984-02-09 1985-09-04 American Cyanamid Company Compositions durcissables à base de résine d'époxyde
EP0395357A2 (fr) * 1989-04-28 1990-10-31 Pfizer Inc. Polyamines utiles comme antagonistes des neurotransmetteurs excitables par aminoacides et/ou comme bloqueurs des canaux de calcium
WO1991000853A1 (fr) * 1989-07-03 1991-01-24 New York University Emploi de polyamines en tant qu'agents regulateurs de canaux ioniques
WO1992008700A1 (fr) * 1990-11-19 1992-05-29 Monsanto Company Inhibiteurs de proteases retrovirales
WO1992014709A2 (fr) * 1991-02-11 1992-09-03 Cambridge Neuroscience, Inc. Antagonistes de canaux de calcium et methodologie d'identification de ces substances
WO1993023368A1 (fr) * 1992-05-20 1993-11-25 G.D. Searle & Co. Composes d'hydroxyethylamine contenant de l'uree utilises comme inhibiteurs de proteases retrovirales
WO1994014436A1 (fr) * 1992-12-29 1994-07-07 Abbott Laboratories Composes inhibant des proteases retrovirales
EP0738711A1 (fr) * 1994-11-04 1996-10-23 Santen Pharmaceutical Co., Ltd. Nouveau derive de 1,3-dialkyluree ayant un groupe hydroxyle
JPH0912455A (ja) * 1995-06-28 1997-01-14 Santen Pharmaceut Co Ltd エンドセリン変換酵素阻害剤
EP0798291A1 (fr) * 1994-12-14 1997-10-01 Santen Pharmaceutical Co., Ltd. Nouveaux derives 1,3-dialkyluree
WO1999007672A1 (fr) * 1997-08-05 1999-02-18 Novo Nordisk A/S Derivees d'anilines 2,5- et 3,5-disubstituees, leur preparation et utilisation
WO1999037604A2 (fr) * 1998-01-21 1999-07-29 Zymogenetics, Inc. Dialkylurees utilisees en tant que substances imitant la calcitonine
WO2000062778A1 (fr) * 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Inhibiteurs cycliques de proteine tyrosine kinase

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS58109464A (ja) 1981-12-23 1983-06-29 Nippon Paint Co Ltd アミノ酸化合物、その製法ならびに触媒
US4579947A (en) * 1983-06-16 1986-04-01 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted phenylalkylpiperazinylpropyl (ureas or thioureas) useful for treatment of immunological, inflammatory and allergic disorder
JPH0841006A (ja) 1994-08-05 1996-02-13 Nisshin Flour Milling Co Ltd ジウレア誘導体
CA2197364A1 (fr) 1996-02-15 1997-08-16 Toshikazu Suzuki Compose phenolique et methode de preparation
JPH10195037A (ja) 1996-02-15 1998-07-28 Tanabe Seiyaku Co Ltd フェノール誘導体
JPH11139969A (ja) 1997-08-07 1999-05-25 Tanabe Seiyaku Co Ltd 医薬組成物
WO1999050238A1 (fr) * 1998-03-26 1999-10-07 Santen Pharmaceutical Co., Ltd. Nouveaux derives d'uree
JP2002515501A (ja) * 1998-05-15 2002-05-28 アボット・ラボラトリーズ レトロウイルスプロテアーゼの阻害化合物

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2001791A1 (fr) * 1968-02-13 1969-10-03 Ciba Geigy
FR2001792A1 (fr) * 1968-02-13 1969-10-03 Ciba Geigy
EP0153576A2 (fr) * 1984-02-09 1985-09-04 American Cyanamid Company Compositions durcissables à base de résine d'époxyde
EP0395357A2 (fr) * 1989-04-28 1990-10-31 Pfizer Inc. Polyamines utiles comme antagonistes des neurotransmetteurs excitables par aminoacides et/ou comme bloqueurs des canaux de calcium
WO1991000853A1 (fr) * 1989-07-03 1991-01-24 New York University Emploi de polyamines en tant qu'agents regulateurs de canaux ioniques
WO1992008700A1 (fr) * 1990-11-19 1992-05-29 Monsanto Company Inhibiteurs de proteases retrovirales
WO1992014709A2 (fr) * 1991-02-11 1992-09-03 Cambridge Neuroscience, Inc. Antagonistes de canaux de calcium et methodologie d'identification de ces substances
WO1993023368A1 (fr) * 1992-05-20 1993-11-25 G.D. Searle & Co. Composes d'hydroxyethylamine contenant de l'uree utilises comme inhibiteurs de proteases retrovirales
WO1994014436A1 (fr) * 1992-12-29 1994-07-07 Abbott Laboratories Composes inhibant des proteases retrovirales
EP0738711A1 (fr) * 1994-11-04 1996-10-23 Santen Pharmaceutical Co., Ltd. Nouveau derive de 1,3-dialkyluree ayant un groupe hydroxyle
EP0798291A1 (fr) * 1994-12-14 1997-10-01 Santen Pharmaceutical Co., Ltd. Nouveaux derives 1,3-dialkyluree
JPH0912455A (ja) * 1995-06-28 1997-01-14 Santen Pharmaceut Co Ltd エンドセリン変換酵素阻害剤
WO1999007672A1 (fr) * 1997-08-05 1999-02-18 Novo Nordisk A/S Derivees d'anilines 2,5- et 3,5-disubstituees, leur preparation et utilisation
WO1999037604A2 (fr) * 1998-01-21 1999-07-29 Zymogenetics, Inc. Dialkylurees utilisees en tant que substances imitant la calcitonine
WO2000062778A1 (fr) * 1999-04-15 2000-10-26 Bristol-Myers Squibb Co. Inhibiteurs cycliques de proteine tyrosine kinase

Non-Patent Citations (18)

* Cited by examiner, † Cited by third party
Title
A.R. VAINO ET AL., PROC. NATL. ACAD. SCI. U.S.A., vol. 97, no. 14, 2000, pages 7692 - 7696 *
DATABASE CHEMABS CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002172378 *
DATABASE CHEMABS CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002172379 *
DATABASE CHEMABS CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002172380 *
DATABASE CHEMABS CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002172382 *
DATABASE CHEMABS CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002172383 *
DATABASE CHEMABS CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002172384 *
DATABASE CHEMABS CHEMICAL ABSTRACT SERVICE, COLUMBUS, OHIO, US; XP002172386 *
J.S. NOWICK ET AL., J. ORG. CHEM., vol. 57, no. 14, 1992, pages 3763 - 3765 *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 117, 1995, DC US, pages 89 - 99, XP002172376 *
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, vol. 119, 1997, DC US, pages 10903 - 10908, XP002172377 *
K.D. MUELLER ET AL., Z. ANORG. ALLG. CHEM, vol. 433, 1977, pages 268 - 274 *
KURO TOSHIHIKO ET AL., BIOL. PHARM. BULL., vol. 23, no. 7, 2000, pages 820 - 825 *
L.T.M. URIBE ET AL., REV. SOC. QUIM. MEX., vol. 22, no. 6, 1978, pages 433 - 435 *
M. NOMURA ET AL., NIHON YUKAGAKKAISHI, vol. 47, no. 11, 1998, pages 1241 - 1249 *
MUNROE J E ET AL, BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 5, no. 23, 7 December 1995 (1995-12-07), pages 2897 - 2902, XP004135189, ISSN: 0960-894X *
PATENT ABSTRACTS OF JAPAN vol. 1997, no. 05 30 May 1997 (1997-05-30) *
V.N. KUKLIN ET AL., KHIM.-FARM. ZH., vol. 30, no. 3, 1996, pages 37 - 41 *

Also Published As

Publication number Publication date
US20070173502A1 (en) 2007-07-26
JP2004535365A (ja) 2004-11-25
FR2820136A1 (fr) 2002-08-02
EP1358171A2 (fr) 2003-11-05
US20040053925A1 (en) 2004-03-18
US7605261B2 (en) 2009-10-20
AU2002233463A1 (en) 2002-08-06
JP4084189B2 (ja) 2008-04-30
CA2435647A1 (fr) 2002-08-01
WO2002059102A2 (fr) 2002-08-01
MXPA03006538A (es) 2003-09-22

Similar Documents

Publication Publication Date Title
WO2002059102A3 (fr) Derives de l'uree, leur procede de preparation, leur application a titre de medicaments, compositions pharmaceutiques et utilisation
AU649849B2 (en) New vanadium complexes, process for preparing them and pharmaceutical compositions containing them
NZ523554A (en) Amino alcohol derivatives
MXPA03007249A (es) Compuestos triazolo como inhibidores de mmp.
IL90062A0 (en) Pyridonecarboxylic acid derivatives,their preparation and pharmaceutical compositions containing them
IL160304A0 (en) ACTIVATOR FOR PEROXISOME PROLIFERATOR-RESPONSIVE RECEPTOR delta
HUT74367A (en) Fungicidal alpha-aryl-substituted cyclic amide derivatives, fungicid compositions containing these as active ingredients and using thereof
EP0775487A4 (fr) Derive de triazine et medicament
WO2002062767A1 (fr) Nouveaux derives de quinazoline
ES2055535T3 (es) Derivados de amina.
HK1050532A1 (en) Novel tetrahydropyridines, preparation method and pharmaceutical compositions containing same
MXPA04005837A (es) Nuevos derivados de benzotiazina y benzotiadiazina, metodo para su preparacion y composiciones farmaceuticas que los contienen.
AU5173293A (en) Novel quaternary ammonium salts and use thereof as medicine
HK1055424A1 (en) Carbamate and thiocarbamate podophyllotoxin derivatives, preparation method and pharmaceutical compositions containing them.
HU9904592D0 (en) New 1,2-dithiolane-derivatives, process for their production and medicaments containing them
HUT59930A (en) Process for producing bis-phosphonic acid derivatives and pharmaceutical compositions containing them as active component
AU2002244985A1 (en) Thiazolidinedione derivatives and pharmaceutical composition comprising the same
MXPA04005839A (es) Nuevos compuestos de benzotiazina y benzotiadiazina un proceso para su preparacion y las composiciones farmaceuticas que los contienen.
HUT57221A (en) Process for producing pyrrolo(2,1-b)thiazol derivatives and pahrmaceutical compositions contiaining them as active components
WO2001046147A8 (fr) Procede de preparation de piperidines 4 substituees
ATE231161T1 (de) 6-deoxy-erythromycin-derivate, ihrer herstellung, und ihrer verwendung als arzneimitteln
HUT53487A (en) Fungicide compositions containing nitrogen-containing heterocyclic compounds as active components and process for producing the active components
MX9710172A (es) Derivados de hidroxilamina anti-isquemicos y composiciones farmaceuticas.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ OM PH PL RO SG SI SK TN TT UA US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CO CR CU CZ DM DZ EC EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MG MK MN MX NO NZ OM PH PL RO SG SI SK TN TT UA US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002700386

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2435647

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/A/2003/006538

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002559404

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 10466571

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002700386

Country of ref document: EP